secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYCOR MEDICAL INC (VYCO)
CIK:        0001424768
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001641172-25-004750
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vycor Medical reports 2024 revenue up 9% to $1.59M; engages Maxim Group for strategic growth
--------------------------------------------------------------------------------

- Revenue $1,589,324 (+9% YoY); Vycor Medical division revenue up 10% to $1,515,744.
- Gross margin 89%; non-GAAP cash operating expenses $1.34M (+$136K); non-GAAP operating profit $81,548 down from $111,084.
- US hospital sales up 17% with 11 new hospitals; eight new peer-reviewed studies published on ViewSite Brain Access System.
- Engaged Maxim Group LLC to assist with corporate strategy including M&A, partnerships, and potential uplisting to a US exchange.
- Products manufactured in US; tariffs not expected to directly impact costs but may affect exports and raw material supply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1424768/000164117225004750/0001641172-25-004750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1424768/000164117225004750/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-004750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer